Integrating New Technologies in Lipidology: A Comprehensive Review

Cardiovascular disease remains the world's leading cause of death, and even when patients reach guideline low-density lipoprotein cholesterol targets, a substantial "residual risk" persists, underscoring the need for more nuanced assessment and intervention. At the same time, rapid advances in high-resolution lipidomics, connected point-of-care diagnostics, and RNA- or gene-based lipid-modifying therapies are transforming what clinicians can measure, monitor, and treat. Integrating multimodal data through machine learning algorithms capable of handling high-dimensional datasets has the potential to improve cardiovascular risk prediction and re-stratification compared to traditional models. This narrative review therefore sets out to (i) trace how these emerging technologies expand our understanding of dyslipidemia beyond the traditional lipid panel, (ii) examine their potential to enable earlier, more personalized and durable cardiovascular risk reduction, and (iii) highlight the scientific, regulatory and ethical hurdles that must be cleared before such innovations can deliver widespread, equitable benefit.